Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Pegfilgrastim-apgf (Nyvepria) a Benefit of Texas Medicaid Effective April 1, 2021

Last updated on

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to eligible clients. Administrative procedures such as prior authorization, pre-certification, referrals, and claims/encounter data filing may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the client's specific MCO for details.

Effective for dates of service on or after April 1, 2021, pegfilgrastim-apgf (Nyvepria) (procedure code Q5122) is a benefit of Texas Medicaid.

Pegfilgrastim-apgf (Nyvepria) (procedure code Q5122) is a granulocyte colony stimulating factor, and is diagnosis restricted.

Refer to: The current Texas Medicaid Provider Procedures Manual, Outpatient Drug Services Handbook, subsection 7.18, “Colony Stimulating Factors (Filgrastim, Pegfilgrastim, and Sargramostim),” for a list of payable diagnosis codes for colony stimulating factors.

For more information, call the TMHP Contact Center at 800-925-9126.